Biomarkers of rheumatoid arthritis-associated interstitial lung disease

Arthritis and Rheumatology

Volumn 67, Issue 1, 2015, Pages 28-38

  Chen, Juan ^a   Doyle, Tracy J ^b   Liu, Yongliang ^c   Aggarwal, Rohit ^d   Wang, Xiaoping ^a   Shi, Yonghong ^a   Ge, Sheng Xiang ^c   Huang, Heqing ^a   Lin, Qingyan ^a   Liu, Wen ^a   Cai, Yongjin ^a   Koontz, Diane ^d   Fuhrman, Carl R ^d   Golzarri, Maria F ^b   Liu, Yushi ^b,e   Hatabu, Hiroto ^b   Nishino, Mizuki ^b   Araki, Tetsuro ^b   Dellaripa, Paul F ^b   Oddis, Chester V ^d   Rosas, Ivan O ^b,f   Ascherman, Dana P ^f,g   more..

^a THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY   (China)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c XIAMEN UNIVERSITY   (China)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e ELI LILLY AND COMPANY   (United States)

^f LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; LEFLUNOMIDE; MATRILYSIN; MATRIX METALLOPROTEINASE; METHOTREXATE; PREDNISONE;

ADULT; ARTICLE; BLOOD; CELL DIFFERENTIATION; CHINESE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSESSMENT; ENVIRONMENTAL FACTOR; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OPEN LUNG BIOPSY; RHEUMATOID ARTHRITIS; SOLID; AGED; CHINA; COMPARATIVE STUDY; COMPLICATION; LUNG DISEASES, INTERSTITIAL; LUNG FUNCTION TEST; MIDDLE AGED; PROCEDURES; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; UNITED STATES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CHEMOKINE CXCL10; CHINA; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MATRIX METALLOPROTEINASE 7; MIDDLE AGED; REGRESSION ANALYSIS; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 84919905591     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38904     Document Type: Article

References (37)

1. Turesson C, O'Fallon WM, Crowson CS, Gabriel SE, Matteson EL,. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis 2003; 62: 722-7.
2. Minaur NJ, Jacoby RK, Cosh JA, Taylor G, Rasker JJ,. Outcome after 40 years with rheumatoid arthritis: a prospective study of function, disease activity, and mortality. J Rheumatol Suppl 2004; 69: 3-8.
3. Olson AL, Swigris JJ, Sprunger DB, Fischer A, Fernandez-Perez ER, Solomon J, et al. Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Resp Crit Care Med 2011; 183: 372-8.
4. Brown KK,. Rheumatoid lung disease. Proc Am Thorac Soc 2007; 4: 443-8.
5. Bongartz T, Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, et al. Incidence and mortality of interstitial lung disease in rheumatoid arithritis: a population-based study. Arthritis Rheum 2010; 62: 1583-91.
6. Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR,. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax 2001; 56: 622-7.
7. Cervantes-Perez P, Toro-Perez AH, Rodriguez-Jurado P,. Pulmonary involvement in rheumatoid arthritis. JAMA 1980; 243: 1715-9.
8. Gabbay E, Tarala R, Will R, Carroll G, Adler B, Cameron D, et al. Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med 1997; 156: 528-35.
9. Doyle TJ, Hunninghake GM, Rosas IO,. Subclinical interstitial lung disease: why you should care. Am J Resp Crit Care Med 2012; 185: 1147-53.
10. Gochuico BR, Avila NA, Chow CK, Novero LJ, Wu HP, Ren P, et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med 2008; 168: 159-66.
11. Chen J, Shi Y, Wang X, Huang H, Ascherman D,. Asymptomatic preclinical rheumatoid arthritis-associated interstitial lung disease. Clin Dev Immunol 2013; 2013: 406927.
12. Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR,. Predictors of progression of HRCT diagnosed fibrosing alveolitis in patients with rheumatoid arthritis. Ann Rheum Dis 2002; 61: 517-21.
13. Ascherman DP,. Interstitial lung disease in rheumatoid arthritis. Curr Rheumatol Rep 2010; 12: 363-9.
14. Doyle TJ, Pinto-Plata V, Morse D, Celli B, Rosas IO,. The expanding role of biomarkers in the assessment of smoking-related parenchymal lung diseases. Chest 2012; 142: 1027-34.
15. Luukkainen R, Saltyshev M, Pakkasela R, Nordqvist E, Huhtala H, Hakala M,. Relationship of rheumatoid factor to lung diffusion capacity in smoking and non-smoking patients with rheumatoid arthritis. Scand J Rheumatol 1995; 24: 119-20.
16. Kinoshita F, Hamano H, Harada H, Kinoshita T, Igishi T, Hagino H, et al. Role of KL-6 in evaluating the disease severity of rheumatoid lung disease: comparison with HRCT. Respir Med 2004; 98: 1131-7.
17. Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006; 54: 38-46.
18. Inui N, Enomoto N, Suda T, Kageyama Y, Watanabe H, Chida K,. Anti-cyclic citrullinated peptide antibodies in lung diseases associated with rheumatoid arthritis. Clin Biochem 2008; 41: 1074-7.
19. Harlow L, Rosas IO, Gochuico BR, Mikuls TR, Dellaripa PF, Oddis CV, et al. Identification of citrullinated Hsp90 isoforms as novel autoantigens in rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheum 2013; 65: 869-79.
20. Rosas IO, Richards TJ, Konishi K, Zhang Y, Gibson K, Lokshin AE, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med 2008; 5: 623-33.
21. Richards TJ, Kaminski N, Baribaud F, Flavin S, Brodmerkel C, Horowitz D, et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Resp Crit Care Med 2012; 185: 67-76.
22. Pardo A, Selman M,. Matrix metalloproteases in aberrant fibrotic tissue remodeling. Proc Am Thorac Soc 2006; 3: 383-8.
23. Richards TJ, Eggebeen A, Gibson K, Yousem S, Fuhrman C, Gochuico BR, et al. Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease. Arthritis Rheum 2009; 60: 2183-92.
24. Shimizu S, Yoshinouchi T, Niimi T, Ohtsuki Y, Fujita J, Maeda H, et al. Differing distributions of CXCR3- and CCR4-positive cells among types of interstitial pneumonia associated with collagen vascular diseases. Virchows Arch 2007; 450: 51-8.
25. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
26. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL,. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
27. Eakin EG, Resnikoff PM, Prewitt LM, Ries AL, Kaplan RM,. Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego. Chest 1998; 113: 619-24.
28. Washko GR, Hunninghake GM, Fernandez IE, Nishino M, Okajima Y, Yamashiro T, et al. Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med 2011; 364: 897-906.
29. Washko GR, Lynch DA, Matsuoka S, Ross JC, Umeoka S, Diaz A, et al. Identification of early interstitial lung disease in smokers from the COPDGene Study. Acad Radiol 2010; 17: 48-53.
30. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1991; 144: 1202-18.
31. Hankinson JL, Odencrantz JR, Fedan KB,. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999; 159: 179-87.
32. Gorelick E, Landsittel D, Marrangoni A, Modugno F, Velikokhatnaya L, Winans MT, et al. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 981-7.
33. Van Bon L, Affandi AJ, Broen J, Christmann RB, Marijnissen RJ, Stawski L, et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med 2014; 370: 433-43.
34. Yanaba K, Hasegawa M, Takehara K, Sato S,. Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis. J Rheumatol 2004; 31: 1112-20.
35. Greene KE, King TE, Kuroki Y, Bucher-Bartelson B, Hunninghake GW, Newman LS, et al. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J 2002; 19: 439-46.
36. Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M,. New serum indicator of interstitial pneumonitis activity: sialylated carbohydrate antigen KL-6. Chest 1989; 96: 68-73.
37. Sato S, Nagaoka T, Hasegawa M, Nishijima C, Takehara K,. Elevated serum KL-6 levels in patients with systemic sclerosis: association with the severity of pulmonary fibrosis. Dermatology 2000; 200: 196-201.